Establishment of the first WHO international genetic reference panel for Prader Willi and Angelman syndromes

Jennifer Boyle1, Malcolm Hawkins, David E Barton

  • 1National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Herts, UK. Jennifer.Boyle@nibsc.hpa.org.uk

Insights

A new international genetic reference panel for Prader Willi and Angelman syndromes has been developed. This panel provides essential, stable reference materials to improve the accuracy of molecular genetic diagnosis for these complex disorders.

Area of Science:

  • Genetics
  • Molecular Biology
  • Clinical Diagnostics

Background:

  • Prader Willi and Angelman syndromes are distinct genetic disorders affecting chromosome 15q11-q13.
  • Accurate molecular diagnosis is crucial but challenging due to complex genetics and lack of standardized reference materials.

Purpose of the Study:

  • To develop and validate a stable, characterized international genetic reference panel for Prader Willi and Angelman syndromes.
  • To improve the accuracy and reliability of molecular diagnostic testing for these conditions.

Main Methods:

  • Development of six genotyping reference materials representing common genetic causes (deletions, UPD, imprinting defects, mutations).
  • Bulk DNA extraction from lymphoblastoid cell lines and freeze-drying for long-term stability.
  • Collaborative study involving 37 laboratories worldwide to assess panel suitability using routine diagnostic methods.

Main Results:

  • Successful development of a panel with diverse genetic causes for both syndromes.
  • Demonstrated stability and suitability of the reference materials through a global collaborative study.
  • Establishment of the first International Genetic Reference Panel for Prader Willi and Angelman syndromes by the WHO.

Conclusions:

  • The developed panel provides a vital resource for accurate molecular diagnosis of Prader Willi and Angelman syndromes.
  • This international reference panel addresses the unmet need for characterized materials, enhancing diagnostic consistency globally.
  • The panel's establishment marks a significant advancement in standardizing genetic testing for these rare disorders.